StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Cytokinetics (CYTK) PT Lowered to $85 at Jefferies
May 23, 2024 5:59 AM
Jefferies analyst Akash Tewari lowered the price target on Cytokinetics (NASDAQ: CYTK) to $85.00 (from $95.00) while maintaining a Buy ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Cytokinetics (CYTK) Prices 9.8M Share Offering at $51/sh
May 23, 2024 3:52 AM
Cytokinetics (CYTK) PT Lowered to $95 at Barclays
May 23, 2024 3:32 AM
Cytokinetics Announces Pricing of Public Offering of Common Stock
May 22, 2024 11:30 PM
After-hours movers: NVIDIA, DuPont, V.F. Corp., and more
May 22, 2024 5:21 PM
Form 424B5 CYTOKINETICS INC
May 22, 2024 4:55 PM
Royalty Pharma plc (RPRX) and Cytokinetics (CYTK) Announce Expanded Strategic Funding Collaboration
May 22, 2024 4:33 PM
Cytokinetics (CYTK) Announces Proposed Public Offering of Common Stock
May 22, 2024 4:32 PM
Form 8-K CYTOKINETICS INC For: May 22
May 22, 2024 4:16 PM
Form 8-K CYTOKINETICS INC For: May 22
May 22, 2024 4:14 PM
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 22, 2024 4:10 PM
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 22, 2024 4:10 PM
Cytokinetics Announces Proposed Public Offering of Common Stock
May 22, 2024 4:02 PM
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 22, 2024 4:00 PM
